Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Says

09/22/2021 | 07:20am EDT


ę MT Newswires 2021
All news about PFIZER, INC.
07:08aAMGEN : Capitol Hill drug pricing reform opponents among the biggest beneficiaries of phar..
RE
05:51aFORMER EMPLOYEE : Pfizer is like an 'abusive, rich husband' with frequent virtue signallin..
AQ
05:10aPFIZER : Prime Minister issues vaccine call to arms ahead of winter
AQ
04:04aPFIZER : United States Donates 1.4 Million More COVID-19 Pfizer Vaccines to Egypt
AQ
10/24NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/24MODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
10/24MODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
10/23PFIZER : United States Donates 1.4 Million More COVID-19 Pfizer Vaccines to Egypt Third Sh..
AQ
10/22Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/22PFIZER : says COVID-19 vaccine more than 90% effective in kids
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,7x
Yield 2021 3,66%
Capitalization 242 B 242 B -
EV / Sales 2021 3,33x
EV / Sales 2022 3,79x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 43,16 $
Average target price 45,72 $
Spread / Average Target 5,94%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.17.25%241 985
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
ELI LILLY AND COMPANY44.37%220 979
MERCK & CO., INC.-0.79%205 421